ACR Meeting Abstracts
Meetings
ACR Convergence 2023
2023 ACR/ARP PRSYM
ACR Convergence 2022
ACR Convergence 2021
ACR Convergence 2020
2020 ACR/ARP PRSYM
2019 ACR/ARP Annual Meeting
2018-2009 Meetings
Download Abstracts
Keyword Index
Advanced Search
Your Favorites
Favorites
Login
View and print all favorites
Clear all your favorites
ACR Meetings
Session » Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities
Meeting:
2013 ACR/ARHP Annual Meeting
Abstract Number: 1732
Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study
Abstract Number: 1733
Early and Sustained Improvement In Pain and Physical Function As Measured By Visual Analog Scale and Short Form-36 Physical Component Summary Score In Rheumatoid Arthritis Patients Treated With Mavrilimumab, An Investigational Anti-GM-CSFR-Alpha Monoclonal Antibody, In a Phase 2a Study
Abstract Number: 1734
A Phase Ib Clinical Trial With Dekavil (F8-IL10), An Immunoregulatory ‘Armed Antibody’ For The Treatment Of Rheumatoid Arthritis, Used In Combination With Methotrexate
Abstract Number: 1735
A Phase IIb Study Of The Efficacy and Safety Of Subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) With Or Without Methotrexate In Adults With Moderate-To-Severe Active Rheumatoid Arthritis and An Inadequate Response To Methotrexate
Abstract Number: 1736
A Randomized, Controlled, Multicenter, 2‑Arm, Parallel‑Group, Double-Blind Study To Demonstrate The Equivalence Of CT-P10 To Innovator Rituximab With Respect To Pharmacokinetic Profile In Patients With Rheumatoid Arthritis
Abstract Number: 1737
Association Of HLA-DRB1 Alleles With Clinical Responses To The Anti-Interleukin−17A Monoclonal Antibody Secukinumab In a Cohort Of Patients With Active Rheumatoid Arthritis: An Exploratory Phase 2 Biomarker Study
« View all sessions from this meeting